Biotechnology Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck’s Pneumococcal Shots – Analyst Says – Vaxcyte (NASDAQ:PCVX) Read more
Biotechnology The Most Important Catalyst For Merck’s Stock In 2024 Could Be Sotatercept Launch, Analyst Says – Merck & Co (NYSE:MRK) Read more
Stockmarkets US FDA approves Merck’s therapy for rare lung condition Reuters via biedexmarkets.com Read more
Biotechnology After Failed Prostate Cancer Study Merck’s Keytruda Combination Therapy Flunks In Late-Stage Lung Cancer Study – Merck & Co (NYSE:MRK) Read more
Biotechnology Newly Diagnosed Cervical Cancer Patients – Merck’s Blockbuster Drug Keytruda Plus Chemoradiotherapy Improves Overall Survival – Merck & Co (NYSE:MRK) Read more
Biotechnology Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead’s and Merck’s Combo Therapy – Merck & Co (NYSE:MRK), Gilead Sciences (NASDAQ:GILD) Read more
Biotechnology Merck’s Multi-Billion Cancer Drug Keytruda Improves Disease-Free Survival In Advanced Bladder Cancer After Surgery, Data Shows – Merck & Co (NYSE:MRK) Read more